Skip to Content
Merck
  • Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.

Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway.

Oncotarget (2017-12-22)
Mathieu Chocry, Ludovic Leloup, Hervé Kovacic
ABSTRACT

Oxaliplatin is a major treatment for metastatic colorectal cancer, however its effectiveness is greatly diminished by the development of resistances. Our previous work has shown that oxaliplatin efficacy depends on the reactive oxygen species (ROS) produced by Nox1. In this report, we investigated Nox1 involvement in the survival mechanisms of oxaliplatin resistant cell lines that we have selected. Our results show that basal ROS production by Nox1 is increased in resistant cells. Whereas the transitory Nox1-dependent production of superoxide contributes to the cytotoxicity of oxaliplatin in sensitive cells, oxaliplatin treatment of resistant cells leads to a decrease in the production of superoxide associated with an increase of H

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diphenyleneiodonium chloride, ≥98%
Sigma-Aldrich
MISSION® esiRNA, targeting human NOX1
Sigma-Aldrich
Anti-Vinculin antibody, Mouse monoclonal, clone hVIN-1, purified from hybridoma cell culture
Sigma-Aldrich
Anti-GAPDH antibody, Mouse monoclonal, clone GAPDH-71.1, purified from hybridoma cell culture
Sigma-Aldrich
MISSION® esiRNA, targeting human CAPN2
Sigma-Aldrich
MISSION® esiRNA, targeting human CAPN1